Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Todd Davis Acquires 35,948 Shares

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Todd Davis bought 35,948 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was bought at an average cost of $27.82 per share, with a total value of $1,000,073.36. Following the completion of the purchase, the director directly owned 75,834 shares in the company, valued at approximately $2,109,701.88. The trade was a 90.13% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pelthos Therapeutics Stock Down 3.6%

Shares of PTHS traded down $1.00 during midday trading on Monday, reaching $26.50. The company had a trading volume of 64,697 shares, compared to its average volume of 13,799. Pelthos Therapeutics Inc. has a 1-year low of $11.20 and a 1-year high of $54.29. The company has a market capitalization of $92.22 million, a PE ratio of -1.28 and a beta of 3.17. The business has a 50 day simple moving average of $25.22. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.86 and a current ratio of 2.79.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last issued its earnings results on Thursday, May 14th. The company reported ($3.09) earnings per share (EPS) for the quarter. The business had revenue of $10.91 million during the quarter. As a group, sell-side analysts anticipate that Pelthos Therapeutics Inc. will post -11.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pelthos Therapeutics

A number of hedge funds have recently modified their holdings of PTHS. Persistent Asset Partners Ltd grew its holdings in shares of Pelthos Therapeutics by 150.0% during the 4th quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock worth $186,000 after purchasing an additional 3,604 shares during the period. Pale Fire Capital SE boosted its holdings in Pelthos Therapeutics by 59.5% during the 1st quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock valued at $271,000 after acquiring an additional 4,819 shares during the period. Millennium Management LLC purchased a new position in Pelthos Therapeutics during the 4th quarter valued at about $343,000. Geode Capital Management LLC boosted its holdings in Pelthos Therapeutics by 31.9% during the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock valued at $422,000 after acquiring an additional 3,295 shares during the period. Finally, Knott David M Jr boosted its holdings in Pelthos Therapeutics by 9.3% during the 1st quarter. Knott David M Jr now owns 21,073 shares of the company’s stock valued at $443,000 after acquiring an additional 1,792 shares during the period. 77.96% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Roth Mkm cut their target price on Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Zacks Research upgraded Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 24th. Piper Sandler started coverage on Pelthos Therapeutics in a report on Friday, February 27th. They set an “overweight” rating and a $48.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Pelthos Therapeutics in a report on Thursday, March 19th. Finally, Cantor Fitzgerald started coverage on Pelthos Therapeutics in a report on Wednesday, April 1st. They set an “overweight” rating and a $50.00 price target for the company. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Pelthos Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $55.80.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).